ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?

dc.bibliographicCitation.firstPage527eng
dc.bibliographicCitation.issue5eng
dc.bibliographicCitation.journalTitleVaccineseng
dc.bibliographicCitation.volume9eng
dc.contributor.authorClemen, Ramona
dc.contributor.authorBekeschus, Sander
dc.date.accessioned2022-04-21T12:04:16Z
dc.date.available2022-04-21T12:04:16Z
dc.date.issued2021
dc.description.abstractCancer is the second leading cause of death worldwide. Today, the critical role of the immune system in tumor control is undisputed. Checkpoint antibody immunotherapy augments existing antitumor T cell activity with durable clinical responses in many tumor entities. Despite the presence of tumor-associated antigens and neoantigens, many patients have an insufficient repertoires of antitumor T cells. Autologous tumor vaccinations aim at alleviating this defect, but clinical success is modest. Loading tumor material into autologous dendritic cells followed by their laboratory expansion and therapeutic vaccination is promising, both conceptually and clinically. However, this process is laborious, time-consuming, costly, and hence less likely to solve the global cancer crisis. Therefore, it is proposed to re-focus on personalized anticancer vaccinations to enhance the immunogenicity of autologous therapeutic tumor vaccines. Recent work re-established the idea of using the alarming agents of the immune system, oxidative modifications, as an intrinsic adjuvant to broaden the antitumor T cell receptor repertoire in cancer patients. The key novelty is the use of gas plasma, a multi-reactive oxygen and nitrogen species-generating technology, for diversifying oxidative protein modifications in a, so far, unparalleled manner. This significant innovation has been successfully used in proof-of-concept studies and awaits broader recognition and implementation to explore its chances and limitations of providing affordable personalized anticancer vaccines in the future. Such multidisciplinary advance is timely, as the current COVID-19 crisis is inexorably reflecting the utmost importance of innovative and effective vaccinations in modern times.eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/8770
dc.identifier.urihttps://doi.org/10.34657/7808
dc.language.isoengeng
dc.publisherBasel : MDPIeng
dc.relation.doihttps://doi.org/10.3390/vaccines9050527
dc.relation.essn2076-393X
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subject.ddc610eng
dc.subject.otherAntigeneng
dc.subject.otherCold physical plasmaeng
dc.subject.otherGas plasma technologyeng
dc.subject.otherImmunogenicityeng
dc.subject.otherOxidative post-translational modificationseng
dc.subject.otherOxPTMeng
dc.subject.otherReactive nitrogen specieseng
dc.subject.otherReactive oxygen specieseng
dc.titleROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?eng
dc.typeArticleeng
dc.typeTexteng
tib.accessRightsopenAccesseng
wgl.contributorINPeng
wgl.subjectMedizin, Gesundheiteng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ros_cocktails_as_an_adjuvant_for_personalized_antitumor_vaccination.pdf
Size:
5.62 MB
Format:
Adobe Portable Document Format
Description: